Abstracts tagged "spondyloarthritis"

Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Jean Liew¹, S. Reza Jafarzadeh², Maureen Dubreuil³, Susan Heckbert⁴, Stephen Mooney⁴, Matthew Brown⁵, Mariko Ishimori⁶, John Reveille⁷, Michael Ward⁸, Michael Weisman⁹ and Lianne Gensler¹⁰, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine/ VA Boston, Boston, MA, ⁴University of Washington, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁸Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…
Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Javier Marrugo¹, Maude Bonin¹, Gilles Boire¹, Louis Bessette² and Ariel Masetto¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…
Abstract Number: 1317 • ACR Convergence 2021
Impairment of Memory in Axial Spondyloarthritis?
Stefan Kleinert¹, Florian Schuch², Praxedis Rapp², Monika Ronneberger², Joerg Wendler², Patrizia Sternad³, Florian Popp³, Peter Bartz-Bazzanella⁴, Cay Von der Decken⁵, Kirsten Karberg⁶, Georg Gauler⁷, Patrick Wurth⁸, Susanna Späthling-Mestekemper⁹, Christoph Kuhn¹⁰, Mathias Englbrecht¹¹, Wolfgang Vorbrüggen¹², Georg Adler¹³ and Martin Welcker¹⁴, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ³Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ⁴Rhein-Maas Klinikum, Wuerselen, Germany, ⁵Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷rheumapraxis, Osnabrck, Germany, ⁸Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁹Rheumapraxis München, München, Germany, ¹⁰Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹¹Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹²Verein zur Förderung der Rheumatologie e.V., Würselen, Germany, ¹³Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany, ¹⁴MVZ für Rheumatologie, Planegg, Germany
Background/Purpose: There is certain evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis (2). However, there is little knowledge about possible cognitive changes…
Abstract Number: 1790 • ACR Convergence 2021
Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
Haruki Sawada¹, Mitsumasa Kishimoto², Kurisu Tada¹, Gautam Deshpande³, Daiki Kobayashi⁴, Keisuke Ono⁵, Yoshinori Taniguchi⁶, Ayako Hirata⁷, Hideto Kameda⁷, Shigeyoshi Tsuji⁸, Yuko Kaneko⁹, Tadashi Okano¹⁰, Yoichiro Haji¹¹, Hiroaki Dobashi¹², Akimichi Morita¹³, Akihiko Asahina¹⁴, Masato Okada¹⁵, Tetsuya Tomita¹⁶, Diego Benavent¹⁷, Chamaida Plasencia-Rodríguez¹⁸, Victoria Navarro-Compán¹⁷, Clementina López Medina¹⁹, Anna Molto²⁰, Désirée van der Heijde²¹, Maxime Dougados²² and Naoto Tamura¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ²Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ³Department of General Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁶Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Nankoku, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁸Department of Orthopedics and Rheumatology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ¹¹Department of Rheumatology, Daido Hospital, Nagoya, Japan, ¹²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ¹³Department of Geriatric and Environmental Dermatology, Nagoya City University, Nagoya, Japan, ¹⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ¹⁵Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ¹⁶Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁷Rheumatology service, Hospital Universitario La Paz-IdiPaz, madrid, Spain, ¹⁸Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ¹⁹Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²⁰Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France
Background/Purpose: Psoriatic arthritis (PsA) shares genetic and clinical features with other forms of spondyloarthritis (SpA). However, no studies have evaluated regional differences regarding characteristics of…
Abstract Number: 0064 • ACR Convergence 2021
Prevalence, Incidence and Predictor Features of Uveitis in Spondyloarthritis in a Canadian Cohort
Vanessa Ocampo¹, Mitchell Sutton², Steve Ramkissoon¹, Alexander Kaplan³, Nigil Haroon⁴ and Dafna Gladman⁵, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Spondyloarthritis (SpA) encompasses Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Inflammatory bowel disease- associated spondyloarthritis (IBD-SpA), Reactive Arthritis (ReA), and undifferentiated spondyloarthritis. These conditions share…
Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Miranda van Lunteren¹, Anne Boel¹, Clementina López Medina², Joachim Sieper³, Désirée van der Heijde⁴ and Floris van Gaalen¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
Abstract Number: 0451 • ACR Convergence 2021
Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Valeria Rios Rodriguez¹, Maryna Verba², Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Hildrun Haibel³, Martin Rudwaleit⁴, Joachim Sieper³ and Denis Poddubnyy⁵, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁵Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on…
Abstract Number: 0913 • ACR Convergence 2021
Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
Désirée van der Heijde¹, Lianne Gensler², Walter Maksymowych³, Robert Landewé⁴, Martin Rudwaleit⁵, Lars Bauer⁶, Bengt Hoepken⁶, Thomas Kumke⁶, Mindy Kim⁷ and Atul Deodhar⁸, ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Department of Rheumatology, University of California San Francisco, San Francisco, CA, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Smyrna, GA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or…
Abstract Number: 0939 • ACR Convergence 2021
Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience
Elif Ediboglu¹, Dilek Solmaz², Gokhan Kabadayi³, eda otman¹, Haluk Cinaklı¹, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Cigli Education and Research Hospital, İzmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Bacground: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is…
Abstract Number: 1318 • ACR Convergence 2021
Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
Richard Howard¹, Michael Weisman², Hedley Hamilton³, Cassie Shafer¹, Elin Aslanyan¹, John Reveille⁴, Kevin Winthrop⁵, Dongseok Choi⁵, Kimbery Ogle⁵, Sarah Siegel⁵, Emily Papaspyru³, Donna Grims¹ and James T. Rosenbaum⁶, ¹Spondylitis Association of America, Encino, CA, ²Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Any-3, London, United Kingdom, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Oregon Health & Science University, Portland, OR, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: The Covid-19 pandemic has been especially challenging for patients with inflammatory diseases including spondyloarthritis (SpA). Patients with rheumatic and musculoskeletal diseases (RMDs) remain at…
Abstract Number: 1791 • ACR Convergence 2021
Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry
Ignacio Gomez-Garcia¹, Teresa García-Puga², Nuria Barbarroja³, Mara ngeles Puche Larrubia⁴, Pilar Font⁵ and Clementina López Medina⁶, ¹Rheumatology Department, Reina Sofia University Hospital. Cordoba (Spain) / University of Cordoba (Spain) / Maimonides Institute for Biomedical Research (IMIBIC). Cordoba (Spain) / Physical Medicine and Rehabilitation Department. Infanta Margarita Hospital. Cabra (Spain), Córdoba, Spain, ²University of Cordoba, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁴Hospital Universitario Reina Sofía, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: To describe if the time of the onset of psoriasis (Pso) relative to the appearance of rheumatic symptoms in patients with spondyloarhtritis (SpA) is…
Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova¹, Monika Gregova², Sarka Forejtova¹, Jana Horinkova¹, Michal Tomcik³, Jindriska Gatterova¹, Jiri Vencovsky¹, Karel Pavelka³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Rheumatology Institute Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…
Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…
Abstract Number: 0469 • ACR Convergence 2021
Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial
Xenofon Baraliakos¹, Philipp Sewerin², Eugenio De Miguel³, Effie Pournara⁴, Christine Kleinmond⁵, Ankita Shekhawat⁶, Annette Wiedon⁷ and Frank Behrens⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵ClinProject GmbH, Eurasburg, Germany, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany
Background/Purpose: The heel is a frequently affected anatomical site for enthesitis in spondyloarthritis (SpA).1 Recently, the Outcome Measures in Rheumatology (OMERACT) group developed and validated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].